High- density lipoprotein function is abnormal in idiopathic inflammatory myopathies

Rheumatology (Oxford). 2020 Nov 1;59(11):3515-3525. doi: 10.1093/rheumatology/keaa273.

Abstract

Objective: Damage to the vascular endothelium is strongly implicated in the pathogenesis of idiopathic inflammatory myopathies (IIM). Normally, high-density lipoprotein (HDL) protects the vascular endothelium from damage from oxidized phospholipids, which accumulate under conditions of oxidative stress. The current work evaluated the antioxidant function of HDL in IIM patients.

Methods: HDL's antioxidant function was measured in IIM patients using a cell-free assay, which assesses the ability of isolated patient HDL to inhibit oxidation of low-density lipoproteins and is reported as the HDL inflammatory index (HII). Cholesterol profiles were measured for all patients, and subgroup analysis included assessment of oxidized fatty acids in HDL and plasma MPO activity. A subgroup of IIM patients was compared with healthy controls.

Results: The antioxidant function of HDL was significantly worse in patients with IIM (n = 95) compared with healthy controls (n = 41) [mean (S.d.) HII 1.12 (0.61) vs 0.82 (0.13), P < 0.0001]. Higher HII associated with higher plasma MPO activity [mean (S.d.) 13.2 (9.1) vs 9.1 (4.6), P = 0.0006] and higher oxidized fatty acids in HDL. Higher 5-hydroxyeicosatetraenoic acid in HDL correlated with worse diffusion capacity in patients with interstitial lung disease (r = -0.58, P = 0.02), and HDL's antioxidant function was most impaired in patients with autoantibodies against melanoma differentiation-associated protein 5 (MDA5) or anti-synthetase antibodies. In multivariate analysis including 182 IIM patients, higher HII was associated with higher disease activity and DM diagnosis.

Conclusion: The antioxidant function of HDL is abnormal in IIM patients and may warrant further investigation for its role in propagating microvascular inflammation and damage in this patient population.

Keywords: cardiovascular disease; dermatomyositis; polymyositis.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Amino Acyl-tRNA Synthetases / immunology
  • Autoantibodies / immunology
  • Case-Control Studies
  • Chromatography, Liquid
  • Dermatomyositis / drug therapy
  • Dermatomyositis / immunology
  • Dermatomyositis / metabolism
  • Endothelium, Vascular
  • Fatty Acids / metabolism
  • Female
  • Glucocorticoids / therapeutic use
  • Humans
  • Hydroxyeicosatetraenoic Acids / metabolism
  • Immunologic Factors / therapeutic use
  • Immunosuppressive Agents / therapeutic use
  • Interferon-Induced Helicase, IFIH1 / immunology
  • Lipoproteins, HDL / metabolism*
  • Lipoproteins, LDL / metabolism*
  • Lung Diseases, Interstitial / immunology
  • Lung Diseases, Interstitial / metabolism*
  • Male
  • Middle Aged
  • Myositis / drug therapy
  • Myositis / immunology
  • Myositis / metabolism*
  • Myositis, Inclusion Body / drug therapy
  • Myositis, Inclusion Body / immunology
  • Myositis, Inclusion Body / metabolism
  • Oxidation-Reduction
  • Peroxidase / metabolism
  • Polymyositis / drug therapy
  • Polymyositis / immunology
  • Polymyositis / metabolism
  • Pulmonary Diffusing Capacity
  • Spectrometry, Mass, Electrospray Ionization

Substances

  • Autoantibodies
  • Fatty Acids
  • Glucocorticoids
  • Hydroxyeicosatetraenoic Acids
  • Immunologic Factors
  • Immunosuppressive Agents
  • Lipoproteins, HDL
  • Lipoproteins, LDL
  • oxidized low density lipoprotein
  • 5-hydroxy-6,8,11,14-eicosatetraenoic acid
  • Peroxidase
  • IFIH1 protein, human
  • Interferon-Induced Helicase, IFIH1
  • Amino Acyl-tRNA Synthetases